Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of intravenous Visipaque in myeloma or monoclonal gammopathy
2006-002655-33Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iodixanol (2 cohorts), sponsored by European Institute of Oncology. Primary endpoints: Urinary N-acetyl-β-D-glucosaminidase (NAG) excretion at 24 hours, Serum creatinine level at 72 hours and 1 more. Started Jul 2007; status: completed.
02
Drugs
iodixanol
Beyond the preview
Go deeper on 2006-002655-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002655-33.